$ARTH
Arch Therapeutics, Inc.

2017 Q1 Form 10-Q Financial Statement

#000114420417005299 Filed on February 01, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $1.490M $1.030M $1.340M
YoY Change 71.26% 18.39% 15.52%
% of Gross Profit
Research & Development $709.9K $349.3K $440.0K
YoY Change 83.78% -15.63% 2.33%
% of Gross Profit
Depreciation & Amortization $357.00 $119.00
YoY Change
% of Gross Profit
Operating Expenses $2.204M $1.376M $1.780M
YoY Change 75.67% 7.54% 11.25%
Operating Profit -$2.204M -$1.376M
YoY Change 75.67% 7.54%
Interest Expense $26.82K $25.57K -$30.00K
YoY Change -59.87% -82.21% -107.32%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.870M -$1.400M -$1.820M
YoY Change 49.6% 20.69% 65.45%
Income Tax
% Of Pretax Income
Net Earnings -$1.869M -$1.402M -$1.820M
YoY Change 49.19% 21.17% 65.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.01
Diluted Earnings Per Share -$13.31K -$0.01 -$12.40K
COMMON SHARES
Basic Shares Outstanding 138.6M shares 135.3M shares 134.2M shares
Diluted Shares Outstanding 135.3M shares

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.230M $3.790M $5.040M
YoY Change 332.93% 34.4% 27.27%
Cash & Equivalents $7.230M $3.788M $5.036M
Short-Term Investments
Other Short-Term Assets $350.0K $110.0K $110.0K
YoY Change 288.89% 120.0% 175.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.576M $3.898M $5.144M
YoY Change 330.58% 35.89% 28.51%
LONG-TERM ASSETS
Property, Plant & Equipment $3.816K $4.174K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $3.816K $4.174K $0.00
YoY Change 503.8%
TOTAL ASSETS
Total Short-Term Assets $7.576M $3.898M $5.144M
Total Long-Term Assets $3.816K $4.174K $0.00
Total Assets $7.579M $3.902M $5.144M
YoY Change 330.65% 36.03% 28.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $208.6K $270.0K $374.9K
YoY Change 49.02% 0.8% 61.76%
Accrued Expenses $150.0K $380.0K $600.0K
YoY Change -6.25% 153.33% 140.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $750.0K $900.0K
YoY Change -100.0% 177.78% 91.49%
Total Short-Term Liabilities $362.8K $1.410M $1.879M
YoY Change -9.31% 88.29% 46.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $80.00K
YoY Change -100.0% -100.0% -91.75%
Other Long-Term Liabilities $2.630M $0.00 $30.00K
YoY Change 874.07% -100.0% -85.71%
Total Long-Term Liabilities $2.635M $0.00 $104.5K
YoY Change 111.98% -100.0% -91.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $362.8K $1.410M $1.879M
Total Long-Term Liabilities $2.635M $0.00 $104.5K
Total Liabilities $2.997M $1.410M $1.983M
YoY Change 82.56% -28.01% -19.47%
SHAREHOLDERS EQUITY
Retained Earnings -$24.99M -$21.71M
YoY Change 37.8% 38.11%
Common Stock $29.57M $24.88M
YoY Change 63.0% 44.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.582M $2.490M $3.161M
YoY Change
Total Liabilities & Shareholders Equity $7.579M $3.900M $5.144M
YoY Change 330.65% 35.96% 28.51%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$1.869M -$1.402M -$1.820M
YoY Change 49.19% 21.17% 65.45%
Depreciation, Depletion And Amortization $357.00 $119.00
YoY Change
Cash From Operating Activities -$2.030M -$1.375M -$1.090M
YoY Change 70.59% 20.61% -32.3%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $4.293K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$4.293K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.480M $130.6K 370.0K
YoY Change 13600.0% -83.91%
NET CHANGE
Cash From Operating Activities -2.030M -$1.375M -1.090M
Cash From Investing Activities 0.000 -$4.293K
Cash From Financing Activities 5.480M $130.6K 370.0K
Net Change In Cash 3.450M -$1.249M -720.0K
YoY Change -400.0% 9.54% -204.35%
FREE CASH FLOW
Cash From Operating Activities -$2.030M -$1.375M -$1.090M
Capital Expenditures $0.00 $4.293K
Free Cash Flow -$2.030M -$1.379M
YoY Change 20.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
CY2016Q4 dei Amendment Flag
AmendmentFlag
false
CY2016Q4 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2016Q4 dei Entity Registrant Name
EntityRegistrantName
Arch Therapeutics, Inc.
CY2016Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2016Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2016Q4 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 dei Trading Symbol
TradingSymbol
ARTH
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
138632075 shares
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
0 USD
CY2016Q3 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
26230 USD
CY2016Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
104485 USD
CY2016Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-21714590 USD
CY2016Q4 dei Document Type
DocumentType
10-Q
CY2016Q3 us-gaap Assets Current
AssetsCurrent
5144260 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
110070 USD
CY2016Q4 us-gaap Notes Payable Current
NotesPayableCurrent
754817 USD
CY2016Q3 us-gaap Notes Payable Current
NotesPayableCurrent
899627 USD
CY2016Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 USD
CY2016Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
78255 USD
CY2015Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1279515 USD
CY2016Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-1375931 USD
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
135319847 shares
CY2015Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
108620575 shares
CY2015Q4 us-gaap Share Based Compensation
ShareBasedCompensation
148037 USD
CY2016Q4 us-gaap Share Based Compensation
ShareBasedCompensation
265662 USD
CY2015Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
143747 USD
CY2016Q4 arth Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
5529 USD
CY2015Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10041 USD
CY2016Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2286 USD
CY2015Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
36102 USD
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1026644 USD
CY2015Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
414003 USD
CY2016Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
349287 USD
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
1279515 USD
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
1375931 USD
CY2016Q4 us-gaap Interest Expense
InterestExpense
25570 USD
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-1156655 USD
CY2016Q4 us-gaap Revenues
Revenues
0 USD
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-1401501 USD
CY2015Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
865512 USD
CY2016Q3 us-gaap Liabilities
Liabilities
1983265 USD
CY2016Q3 us-gaap Common Stock Value
CommonStockValue
134432 USD
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
24741153 USD
CY2016Q3 us-gaap Stockholders Equity
StockholdersEquity
3160995 USD
CY2016Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5144260 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1409675 USD
CY2016Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
121036 USD
CY2016Q3 us-gaap Assets
Assets
5144260 USD
CY2016Q4 us-gaap Assets
Assets
3901981 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
3897807 USD
CY2016Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
107784 USD
CY2016Q3 us-gaap Cash
Cash
5036476 USD
CY2016Q4 us-gaap Cash
Cash
3787737 USD
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
261570 USD
CY2016Q3 us-gaap Interest Payable Current
InterestPayableCurrent
304770 USD
CY2015Q4 us-gaap Revenues
Revenues
0 USD
CY2015Q4 us-gaap Interest Expense
InterestExpense
143747 USD
CY2015Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
137146 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
0 USD
CY2015Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
122860 USD
CY2016Q4 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-25570 USD
CY2015Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
129461 USD
CY2016Q4 arth Gain On Exercise Of Warrants
GainOnExerciseOfWarrants
0 USD
CY2016Q4 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-102644 USD
CY2015Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-91734 USD
CY2016Q4 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-178451 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1144651 USD
CY2016Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1375002 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
0 USD
CY2016Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
130556 USD
CY2015Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1144651 USD
CY2016Q4 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1248739 USD
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3960100 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5036476 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2815449 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3787737 USD
CY2015Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0 USD
CY2016Q4 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
359150 USD
CY2015Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-137146 USD
CY2016Q4 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0 USD
CY2016Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
CY2015Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
325896 USD
CY2016Q4 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-108000 USD
CY2015Q4 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-52500 USD
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
4044 USD
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Excluding Capital Leased Assets
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentExcludingCapitalLeasedAssets
3925 USD
CY2013Q2 arth Increase In Aggregate Number Of Shares
IncreaseInAggregateNumberOfShares
3000000 shares
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7657 pure
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.1944 pure
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0064 pure
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0240 pure
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0.00 pure
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedWeightedAverageRemainingContractualTerm
P0Y
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm
P0Y
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedWeightedAverageRemainingContractualTerm
P0Y
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P6Y11D
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y2M8D
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Awarded Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAwardedAggregateIntrinsicValue
0 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodAggregateIntrinsicValue
0 USD
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
2549359 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
3167065 USD
CY2016Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0.42
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.33
CY2016Q4 arth Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
0.32
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.33
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y2M8D
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
5447529 shares
CY2015Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.20
CY2016Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
0 USD
CY2015Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
2800 USD
CY2014Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
224000 USD
CY2015Q1 arth Gain Loss On Warrant Derivative Modification
GainLossOnWarrantDerivativeModification
624016 USD
CY2015Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
3263753 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4174 USD
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 USD
CY2016Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
4174 USD
CY2016Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
0 USD
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
138182075 shares
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
136657075 shares
CY2016Q4 us-gaap Depreciation
Depreciation
119 USD
CY2015Q4 us-gaap Depreciation
Depreciation
0 USD
CY2016Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-69430 USD
CY2015Q4 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0 USD
CY2016Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4293 USD
CY2015Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2016Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-4293 USD
CY2015Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
0 USD
CY2016Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
228594 USD
CY2015Q4 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2016Q4 us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px 0px 0px 0.5in; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> <u>Concentration of Credit Risk</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> &#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif"> Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8218 USD
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3925 USD
CY2016Q4 us-gaap Derivative Fair Value Of Derivative Liability Amount Not Offset Against Collateral
DerivativeFairValueOfDerivativeLiabilityAmountNotOffsetAgainstCollateral
354988 USD
CY2016Q4 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
395012 USD
CY2016Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0 USD
CY2016Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
754817 USD
CY2015Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
977882 USD
CY2016Q4 us-gaap Interest Expense Debt
InterestExpenseDebt
5500 USD
CY2016Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
0 USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4341816 USD
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3167065 USD

Files In Submission

Name View Source Status
0001144204-17-005299-index-headers.html Edgar Link pending
0001144204-17-005299-index.html Edgar Link pending
0001144204-17-005299.txt Edgar Link pending
0001144204-17-005299-xbrl.zip Edgar Link pending
arth-20161231.xml Edgar Link completed
arth-20161231.xsd Edgar Link pending
arth-20161231_cal.xml Edgar Link unprocessable
arth-20161231_def.xml Edgar Link unprocessable
arth-20161231_lab.xml Edgar Link unprocessable
arth-20161231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v457457_10q.htm Edgar Link pending
v457457_ex31-1.htm Edgar Link pending
v457457_ex31-2.htm Edgar Link pending
v457457_ex32-1.htm Edgar Link pending